Sareum’s small molecule drug discovery expertise builds value by developing drug candidates, focused on cancer and autoimmune disease, for licencing to pharmaceutical and biotechnology companies.
Find out more about us
01 May 2020
28 April 2020
26 March 2020
Find out more
The potential of Sareum's SDC-1801 TYK2/JAK1 inhibitor in the fight against Covid-19
Sareum has an innovative pipeline of drug development candidates.
BioTrinity, April 2020 (Video, Slides)Proactive Investors, March 2020 (Video)Half-yearly Results, March 2020 (Slides)
Share price dataRegulatory News Service (RNS)
Sareum LimitedUnit 2A, Langford ArchLondon Road, PampisfordCambridge CB22 3FXUnited Kingdom
tel: +44 (0) 1223 497700fax: +44 (0) 1223 497701
Half-year Results 2019 Brochure Sept 2019
Annual Report 2019